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Abstract
The incidence of pertussis in the United States has increased since the 1990s. Tdap vaccination of 
pregnant women provides passive protection to infants. Tdap vaccination is currently 
recommended for pregnant women during each pregnancy, but coverage among pregnant women 
and women of childbearing age has been suboptimal. Data from the 2013 BRFSS and 2013 NHIS 
were used to determine national and state-specific Tdap vaccination coverage among women of 
childbearing age by self-reported pregnancy status at the time of the survey. Although this study 
could not assess coverage of Tdap vaccination received during pregnancy because questions on 
whether Tdap was received during pregnancy were not asked in BRFSS and NHIS, demographic 
and access-to-care factors associated with Tdap vaccination coverage in this population were 
assessed. Tdap vaccination coverage among all women 18-44 years was 38.4% based on the 
BRFSS and 23.3% based on the NHIS. Overall, coverage did not differ by pregnancy status at the 
time of the survey. Coverage among all women 18-44 years varied widely by state. Age, race/
ethnicity, education, number of children in the household, and access-to-care characteristics were 
independently associated with Tdap vaccination in both surveys. We identified associations of 
demographic and access-to-care characteristics with Tdap vaccination that can guide strategies to 
improve vaccination rates in women during pregnancy.
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The incidence of pertussis in the United States has been increasing since the 1990s. In 2012, 
cases reached the highest reported in nearly 60 years, with 41,880 pertussis cases, 
including14 infant deaths [1, 2]. In 2006, the Advisory Committee on Immunization 
Practices (ACIP) recommended a single dose of tetanus, diphtheria and acellular pertussis 
(Tdap) to adolescents 11-18 years and adults 19-64 years who have not previously received 
Tdap. In addition, ACIP recommended that when possible, women of childbearing age 
should receive Tdap before becoming pregnant as antibodies to pertussis antigens are 
passively transferred during pregnancy [3]. In October 2011, the ACIP recommended that 
unvaccinated women receive a Tdap vaccine during pregnancy, preferably during the third or 
late second trimester (after 20 weeks' gestation) or immediately postpartum, if not 
administered during pregnancy, but did not recommend Tdap vaccination of previously 
vaccinated pregnant women [4]. In February 2013, ACIP revised recommendations to 
vaccination of Tdap during every pregnancy, optimally between 27 and 36 weeks gestation 
to maximize the maternal antibody response and passive antibody transfer to the infant, 
since studies suggested that maternal antipertussis antibodies from women immunized 
during a recent pregnancy waned substantially during the first year after vaccination and a 
single dose of Tdap at one pregnancy would be insufficient to provide adequate protection to 
infants at birth for subsequent pregnancies [5].
Few studies have documented Tdap vaccination coverage among pregnant women since the 
recommendations in 2011 and 2013. One study indicated that 14.3% of pregnant women 
enrolled in Medicaid in Michigan from 2011-2013 received Tdap vaccination during 
pregnancy [6]. Coverage differed by race/ethnicity, and maternal age was a significant 
predictor of vaccination [6]. Another study using data from seven Vaccine Safety Datalink 
(VSD) sites over six years found that in 2012, 56.1% of pregnant women received Tdap 
vaccination before pregnancy, 13.7% during pregnancy, and 8.8% received Tdap within six 
weeks of pregnancy end [7]. Another study using Wisconsin claims data found that 35.0% of 
insured women 11-44 years who delivered between January 2013 and March 2014 received 
Tdap vaccination during pregnancy, and the percentage of women who received Tdap 
vaccination during pregnancy increased from 13.8% among women delivering during 
January 2013 before the updated ACIP recommendation to 51.0% among women delivering 
during March 2014 [8]. Most studies on Tdap vaccination coverage during pregnancy have 
used medical claims data with limited information on socio-demographic and access-to-care 
factors which may be associated with Tdap vaccination. Additionally, a recent study 
reported Tdap vaccination coverage was 45.5% (ever received Tdap) among privately 
insured women of reproductive age and researchers noted the importance of identifying 
strategies to routinize vaccination among women who may become pregnant [9].
Both the Behavioral Risk Factor Surveillance System (BRFSS) and the National Health 
Interview Survey include questions on Tdap vaccination since 2005, but neither survey asks 
women if they received Tdap during pregnancy. While Tdap vaccination received during 
pregnancy cannot be ascertained, the proportion of women of childbearing age (both 
currently pregnant or not pregnant at the time of the survey) who report Tdap vaccination 
since 2005 can be determined and information is available on socio-demographic and 
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access-to-care factors which may be associated with Tdap vaccination. Data from the 2013 
BRFSS and 2013 NHIS were used to examine socio-demographic and access-to-care 
characteristics associated with Tdap vaccination among pregnant and non-pregnant women, 
as well as national and state-level Tdap vaccination coverage. This information may be 
useful in identifying and implementing strategies to improve Tdap vaccination coverage 
among women, especially those of childbearing age.
Methods
Data from the 2013 BRFSS and 2013 NHIS were analyzed in 2015. The BRFSS is a 
continuous, population-based telephone survey conducted by state health departments in 
collaboration with the Centers for Disease Control and Prevention (CDC) and the NHIS is a 
national cross-sectional household survey conducted annually by the CDC. Both surveys 
collect information about the health, health care, and behaviors of the noninstitutionalized 
U.S. civilian population using representative samples. In 2013, the median BRFSS response 
rate among all states, territories, and Washington, D.C. was 46.4% and the NHIS sample 
adult response rate was 61.2% [10, 11]. Methods from these surveys have been previously 
described [11-13].
Women in both surveys were asked whether they were currently pregnant at the time of 
interview. We included women 18-44 years in the analysis stratified by self-reported 
pregnancy status at the time of interview. Women who did not report pregnancy status were 
included in the analysis of “all women”. All NHIS results were reported by less detailed 
demographic and access-to-care variables than those in BRFSS, since there were only 215 
pregnant women in the 2013 NHIS for whom Tdap vaccination information was available 
and thus sample sizes for more detailed variables were very small. Also, some variables 
were available in the BRFSS (time since last routine checkup, ability to see a doctor due to 
cost) that were not available in NHIS.
In BRFSS, respondents were asked the following questions on Tdap vaccination: “Since 
2005, have you had a tetanus shot?” and “Was this Tdap, the tetanus shot that also has 
pertussis or whooping cough vaccine?” NHIS respondents were asked the following three 
questions: “Have you received a tetanus shot in the past 10 years?”, “Was your most recent 
tetanus shot given in 2005 or later?”, and “Thinking back to your most recent tetanus shot, 
did your health care provider tell you or did the vaccine information sheet say the vaccine 
included pertussis or whooping cough vaccine?” Respondents who reported receiving a 
tetanus shot since 2005 but did not know the type were excluded from the analysis. In 
BRFSS, among all women 18-44 years, 37,044 reported receiving any tetanus shot since 
2005, with 18,278 reporting that the vaccine was Tdap, while in NHIS, 4,836 reported 
receiving any tetanus shot since 2005, with 1,305 reporting that the vaccine was Tdap. A 
large percentage (38.8% in BRFSS and 31.3% in NHIS) were excluded from the Tdap 
analysis, and some subgroups had as much as 47% missing (women 18-24 years in BRFSS). 
Sensitivity analyses were conducted to assess the potential magnitude of bias from these 
exclusions, estimating a range of Tdap coverage if respondents excluded had either all 
received or not received Tdap.
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Unadjusted coverage estimates were calculated as the weighted proportion of respondents 
who reported receiving Tdap. Multivariable logistic regression was used to calculate 
differences in predicted marginals adjusted for demographic and access-to-care variables. 
Separate regression models were run for BRFSS and NHIS data. Multicollinearity was 
assessed using condition indices and variance decomposition proportions[14]. State-level 
estimates among women 18-44 years were produced using BRFSS data. T-tests were used to 
make comparisons between groups with a significance level set at α= 0.05. All analyses 
were performed using SAS-callable SUDAAN software version 11.0.
Results
Sample characteristics
Among the 73,540 women 18-44 years from the BRFSS, 2,958 reported being pregnant at 
the time of interview, 69,364 reported not being pregnant, and 1,218 did not have a 
pregnancy status. The majority of women were non-Hispanic white, were a member of a 
married or unmarried couple, had at least some college education, were employed, reported 
an annual household income less than $50,000, reported excellent/very good health, had 
health insurance, had a personal healthcare provider, had a routine checkup within the past 
year, did not report being unable to see a doctor due to cost, and had not had an influenza 
vaccination in the past year (Table 1). The distribution of sample characteristics differed 
between pregnant and non-pregnant women for age, race/ethnicity, marital status, 
employment, number of children living in the household, health status, insurance status, 
whether the respondent had a personal healthcare provider, time since last routine checkup, 
ability to see a doctor due to cost, and influenza vaccination in the past 12 months (Table 1).
A total of 8,244 women 18-44 years were interviewed in NHIS, with 328 pregnant and 7,903 
not pregnant at the time of the survey (13 did not have a pregnancy status). The majority of 
women were 30-44 years, were non-Hispanic white, were a member of a married or 
unmarried couple, had less than a college education, were employed, reported an annual 
family income of at least $35,000, lived with at least one child<18 years, reported excellent/
very good/good health, had health insurance, had a personal healthcare provider, and had not 
been vaccinated for flu in the previous 12 months. The distribution of age, marital status, 
employment status, health insurance status, and whether the respondent had a personal 
healthcare provider differed between pregnant and non-pregnant women (Note: Results 
based on the NHIS are not shown in tables but are available if requested by readers).
Tdap vaccination coverage based on bi-variable analysis
Based on the BRFSS, 38.4% of all women 18-44 years, 41.8% of women pregnant at the 
time of the survey, and 38.2% of women not pregnant at the time of the survey reported 
Tdap vaccination since 2005 (Table 2). Overall, coverage did not differ significantly among 
pregnant and non-pregnant women. Among all women, Tdap vaccination coverage was 
higher among those 18-24 years compared with all other age groups. Coverage was lower 
among non-Hispanic blacks (31.3%) and Hispanics (32.0%) compared with non-Hispanic 
whites (42.3%) and lower among women who were divorced, widowed or separated (30.1%) 
compared with women who were married or members of an unmarried couple (39.3%) 
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(p<0.05). Among women 18-44 years overall, other factors associated with higher Tdap 
coverage included having at least graduated high school, being employed, income of at least 
$35,000 or higher, living in the Midwest, reporting perceived health as better than poor, 
having health insurance, a personal health care provider, and having reported a routine 
checkup in the past year, reporting no cost barriers to seeing a doctor, and reporting being 
vaccinated for influenza in the past 12 months (Table 2). Vaccination coverage was lower 
among women living in the South compared to the Northeast (Table 2).
Among women currently pregnant at the time of the survey, coverage was lower among non-
Hispanic blacks (30.2%) and Hispanics (35.5%) compared with non-Hispanic whites 
(47.3%) and lower among women who were divorced, widowed or separated (17.9%) 
compared with women who were married or members of an unmarried couple (45.5%)
(p<0.05). Characteristics associated with higher Tdap vaccination coverage among women 
pregnant at the time of the survey included having at least graduated high school or higher 
education, reporting income of at least $50,000 or higher, having health insurance and a 
personal health care provider, reporting no cost barriers to seeing a doctor, and reporting 
being vaccinated for influenza in the past 12 months (Table 2). Currently pregnant women 
who lived with at least 3 children had lower coverage (27.5%) than women who lived with 
no children (41.4%) (p<0.05). Among women who reported not being pregnant at the time 
of the survey, characteristics associated with higher Tdap vaccination coverage were similar 
to those among all women 18-44 years. Comparing pregnant women to those not pregnant at 
the time of the survey, Tdap coverage was higher for non-Hispanic whites, women who were 
married or members of an unmarried couple, high school graduates, employed women, 
women in households with an annual income of $50,000-$74,999, and women living with 2 
children. Coverage was higher among non-pregnant women than pregnant women among 
divorced/widowed/separated women and women living with 3 or more children (Table 2).
Based on the NHIS, 23.3% of all women 18-44 years, 25.4% of women pregnant at the time 
of the survey, and 23.2% of women not pregnant at the time of the survey reported having 
received Tdap vaccination since 2005. Overall, coverage did not differ among pregnant and 
non-pregnant women. Among all women, coverage was higher compared with other groups 
among women 18-29 years, non-Hispanic whites, women with at least a college degree, 
women who were employed, women in families with at least an annual income of $35,000, 
insured women, those reporting a personal healthcare provider, and women who had 
received influenza vaccination in the past 12 months. Vaccination coverage was lower 
among women living in the South compared to the Northeast. Among pregnant women, 
coverage was higher among those with at least a college degree, those who were employed, 
women in families with at least an annual income of $35,000, and those who had received 
influenza vaccination in the past 12 months. Coverage among women who were not 
pregnant at the time of the survey was similar to coverage among all women. Comparing 
women who were not pregnant to women who were pregnant, coverage was higher among 
women with an annual household income less than $35,000. A comparison of Tdap 
vaccination coverage based on data from the BRFSS and NHIS using the same demographic 
and access to care categories was made. All the NHIS estimates are substantially lower than 
the respective BRFSS estimates (Note: Results based on the NHIS are not shown in tables 
but are available if requested by readers).
O’Halloran et al. Page 5













Based on the sensitivity analysis, Tdap vaccination among all women 18-44 years could 
have ranged from 28.9% to 53.6% based on the BRFSS and 17.3% to 43.2% based on the 
NHIS.
Tdap vaccination based on multivariable logistic regression and predictive marginals
Based on the BRFSS, adjusted Tdap vaccination coverage among all women 18-44 years 
was higher among women 18-24 years compared to women at least 25 years of age, non-
Hispanic whites compared with non-Hispanic blacks and Hispanics, women with at least 
some college education compared with those without a high school education, women not in 
the work force compared with employed women, women with at least one child in the 
household compared with those not living with children, women living in the Midwest and 
West compared with the Northeast. Tdap vaccination coverage was also higher among 
women with health insurance compared to those without insurance, women with a personal 
healthcare provider compared to those without a provider, women reporting a routine 
checkup in the past year compared to those reporting no routine checkup in the past year, 
and women reporting influenza vaccination in the past 12 months compared to those not 
reporting influenza vaccination. Among pregnant women, adjusted Tdap coverage was lower 
among pregnant women 35-44 years compared with pregnant women 18-24 years, but 
higher among pregnant women with some college compared to those without a high school 
degree, pregnant women with a healthcare provider, and those with an influenza vaccination 
in the past 12 months. Differences in adjusted coverage by demographic and access to care 
characteristics were similar among non-pregnant women and all women. No issues were 
found with multi-collinearity based on regression diagnostics from multivariable logistic 
regression models using the BRFSS data. (Table 3).
Based on the NHIS, adjusted Tdap coverage was lower among all women 30-44 years than 
among women 18-29 years. Among all women, higher adjusted Tdap vaccination coverage 
was associated with non-Hispanic white race, having at least a college education, living with 
at least one child, having health insurance, and reporting receipt of influenza vaccination in 
the past 12 months. Among pregnant women, higher adjusted Tdap coverage was associated 
only with having received influenza vaccination in the past 12 months. Differences in 
adjusted Tdap coverage by demographic and access to care characteristics were similar 
among non-pregnant women and all women. No issues were found with multi-collinearity 
based on regression diagnostics from multivariable logistic regression models using the 
NHIS data. (Note: Results based on the NHIS are not shown in tables but are available if 
requested by readers).
State vaccination coverage
Based on the BRFSS, state Tdap vaccination coverage among all women 18-44 years ranged 
from 24.3% in Florida to 58.6% in Minnesota, with a median of 39.2%. Among the two 
territories, Tdap coverage was 9.8% in Puerto Rico and 25.9% in Guam (Figure 1).
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Higher Tdap vaccination coverage among younger women has been previously reported, 
likely a reflection of success in vaccinating adolescents [9]. Tdap coverage among 
adolescents 17 years in 2012, who would be 18 in 2013, was reported at 83.3% in 2012 [15]. 
Aggregate estimates from the BRFSS were consistently higher than national estimates 
obtained from the NHIS. Although aggregate estimates have been reported from the BRFSS, 
this survey is designed to reflect each state or area’s population and not representative of 
national sampling as is the NHIS. In addition to different sampling frames, other 
methodological differences in these surveys might lead to different estimates, including 
survey mode, survey questions, order of survey questions, survey administration, operations 
and weighting [12, 16]. Despite differences in vaccination coverage estimates, many of the 
same factors associated with Tdap coverage among women of childbearing age were found 
in both surveys.
Racial/ethnic disparities were observed based on the results from BRFSS and NHIS, and 
such differences in Tdap vaccination as well as differences for other vaccines recommended 
for adult populations have been reported previously [6, 16-19]. Differences in attitudes 
toward vaccination, vaccine-seeking behaviors, likelihood of a provider recommendation, 
quality of care received, as well as other factors might contribute to differences in coverage 
among these groups [20-24].
Our analysis found that women living in households with at least one child were more likely 
to be vaccinated than women living in households without any children, although this 
association was not observed among the much smaller subpopulation of currently pregnant 
women. Higher coverage among women living with children could reflect Tdap “cocooning” 
strategies, that is vaccinating adults who have or who anticipate having close contact with an 
infant, which have been recommended since 2006 [3]. Also, women who live with children 
might have a greater propensity for Tdap vaccination as a result of experiences related to 
vaccination of these children and contact with their child’s vaccination providers. Higher 
education was also associated with higher coverage. A previous study found that higher 
education was associated with Tdap vaccine awareness among all adults [25].
Our results indicate that women with health insurance, a personal provider, a recent routine 
checkup, and influenza vaccination in the past 12 months were more likely to report receipt 
of Tdap. Other studies have identified access to care as an important factor associated with 
receipt of Tdap and other vaccines in other adult populations [19, 26]. Having health 
insurance, a regular physician, and seeking medical care one or more times during the year 
provide opportunities for education about Tdap vaccination and other preventive services. 
Association of Tdap vaccination with receipt of influenza vaccine might indicate a positive 
attitude about vaccination and other preventive measures playing an important role in a 
women’s decision about Tdap vaccination. In addition, one study showed that providers play 
an important role in a pregnant woman’s decision to receive influenza vaccination; pregnant 
women who receive a recommendation and an offer of influenza vaccine are more likely to 
be vaccinated (70.5%) than women who received a recommendation but no offer (32.0%) or 
who received no recommendation and no offer (9.7%) [27]. A recent study from providers in 
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New York state found that only 80% of obstetric providers recommended Tdap to all eligible 
patients, and 67% provided the vaccine in their office [28].
Based on the BRFSS, state-level Tdap vaccination coverage varied widely. Variation in state-
level vaccination coverage has been reported for other adult vaccines (e.g., influenza and 
pneumococcal vaccines) [18, 29, 30]. States with the highest/lowest Tdap coverage did not 
necessarily have similar rankings in coverage for other adult vaccines, but there were some 
patterns[18]. Florida and Nevada have consistently ranked in the bottom 5 states for 
influenza vaccination since the 2009-10 season, and likewise are among states with the 
lowest Tdap coverage among women of childbearing age[18]. Rhode Island has ranked in 
the top 5 states for influenza vaccination since the 2010-11 season and also has the 8th 
highest Tdap coverage among women of childbearing age [18]. Variation in state coverage 
could be due to differing medical care delivery infrastructure, population norms, and state 
and local immunization programs [31].
This study has limitations. First, the data sources used could not assess Tdap vaccination 
during the most recent pregnancy. However, identifying factors associated with Tdap 
vaccination among all women of reproductive age might aid in developing strategies to 
improve vaccination in pregnant women as well. Second, sociodemographic and access-to-
care factors were based on the status at the time the respondent was interviewed and may not 
reflect the status when Tdap vaccination was received since vaccination could have occurred 
any time since 2005. Third, Tdap vaccination was based on self-report and subject to recall 
bias. Validity of Td and Tdap vaccination based on BRFSS were not reported; however, self 
report of pneumococcal vaccination based on the BRFSS was validated by medical record, 
and had a sensitivity of 75% and a specificity of 83%[32]. In addition, adult self-reported 
vaccination has been shown to be sensitive (92.1% for tetanus)[33]. A large percentage of 
women 18-44 years were excluded from the analysis, because of data missing on Tdap 
vaccination in large part due to respondents not knowing what type vaccine they 
received(i.e., Td or Tdap).
Conclusion
Age, race/ethnicity, education, number of children in the household, and access-to-care 
characteristics were associated with Tdap vaccination in both surveys. Client reminder and 
recall systems and education efforts on the benefit and safety of Tdap vaccination during 
pregnancy used with standing orders might help increase Tdap coverage among pregnant 
women [34]. Recommendations for Tdap vaccination from providers, particularly 
obstetricians/gynecologists, who are important care givers for women during pregnancy, and 
health care reminder systems also can help improve the uptake of Tdap vaccination in this 
population. Vaccination of pregnant women is the best strategy to prevent pertussis infection 
in newborns.
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Tdap vaccination coverage* among women 18-44 years† by state – United States, BRFSS 
2013
* Tdap vaccination since 2005.
† Includes all women 18-44 years, including those for whom pregnancy status at the time of 
the survey is not available.
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